Clinical trials: Peripheral Arterial Disease, open to volunteers
Peripheral Arterial Disease
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities.
- Trial name
- NCT02842424
- Testing
- Ramipril
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Nebraska
Peripheral Artery Disease, Diabetes Mellitus
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
The aim of this clinical study is to 1) establish a healthy database for nuclear perfusion imaging of the lower extremities and 2) assess the prognostic value of radiotracer-based perfusion imaging for predicting clinical…
- Conditions
- Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
- Trial name
- NCT03622359
- Testing
- SPECT/CT perfusion imaging, PET/CT perfusion imaging
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Peripheral Artery Disease (PAD)
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become…
- Trial name
- ROXI-PALISADE (NCT07318610)
- Testing
- REGN7508, REGN9933, Rivaroxaban
- Where
- 29 sites in United States, United Kingdom
- Volunteers
- 7,050 people
- Sponsor
- Regeneron Pharmaceuticals
Peripheral Artery Disease (PAD)
IV-X Medical Peripheral Intravascular Lithotripsy Study for PAD
To evaluate the safety and performance of the IV-X Medical Intravascular Lithotripsy (IVL) System in adults in order to demonstrate the ability of the IV-X Medical IVL System to safely and effectively deliver IVL treatment…
- Trial name
- HELIX-PAD (NCT07746362)
- Testing
- IV-X Medical IVL System
- Volunteers
- 140 people
- Sponsor
- IVX Medical
Diabetes Mellitus, Peripheral Arterial Disease
Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model
In this study, Logistic regression analysis was used to construct a risk prediction model for ASO in diabetic patients. Guided by the HAPA model, a nursing intervention plan for preventing ASO in diabetic patients was constructed…
- Trial name
- NCT07881588
- Testing
- Routine Care, Experimental group intervention
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Arteriovenous Malformation, Gastrointestinal Bleed
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess…
- Conditions
- Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid
- Trial name
- NCT07639853
- Testing
- Concerto Versa™ Detachable Coils
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medtronic Endovascular
Chronic Limb Threatening Ischemia
Vessel Recoil in Specific CLTI Populations
Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene.
- Trial name
- NCT07465627
- Testing
- Vessel recoil measurement 15 minutes post final treatment (angiographically)
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Graz
Peripheral Vascular Disease, Peripheral Arterial Disease
EVERO Drug-coated Balloon (DCB) Randomized Trial
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero…
- Trial name
- NCT07144150
- Testing
- Evero DCB, Paclitaxel DCB
- Where
- 12 sites in United States
- Volunteers
- 410 people
- Sponsor
- Cook Research Incorporated
Peripheral Arterial Disease
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
- Trial name
- ATTAIN-PAD (NCT07223593)
- Testing
- Orforglipron
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Femoropopliteal Disease, Drug Coated Balloon
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial Disease
The aim of this clinical trial is to determine whether vessel preparation with a non-compliant scoring balloon before drug-coated balloon (DCB) angioplasty provides superior procedural and clinical outcomes compared with vessel…
- Conditions
- Femoropopliteal Disease, Drug Coated Balloon, Critical Limb-Threatening Ischaemia, Peripheral Arterial Disease
- Trial name
- DASBAD-NC (NCT07764016)
- Testing
- Non-compliant Plain Balloon angioplasty (PBA), Non-compliant Scoring Balloon Angioplasty (SB)
- Volunteers
- 142 people
- Sponsor
- Marc Sirvent
Peripheral Arterial Disease
Hemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics
Peripheral arterial disease can reduce blood flow to the legs. This study will examine how blood flow patterns in the leg arteries differ between people with peripheral arterial disease and people without the disease.
- Trial name
- NCT07860138
- Testing
- Computational Fluid Dynamics Simulation
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Fudan University
Peripheral Arterial Disease, Atherosclerosis of Extremities
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with…
- Conditions
- Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
- Trial name
- LEADER-PAD (NCT04774159)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 6,150 people
- Sponsor
- Population Health Research Institute
Aneurysm Abdominal, Peripheral Arterial Disease
Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression
The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral…
- Trial name
- VASCULAIDRETRO (NCT06206369)
- Testing
- No intervention, retrospective study
- Where
- 6 sites in Finland, Germany and 4 more
- Volunteers
- 11,000 people
- Sponsor
- Amsterdam UMC, location VUmc
Peripheral Artery Disease, Intermittent Claudication
Improving Mobility After Revascularization in Peripheral Artery Disease
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia.
- Conditions
- Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation
- Trial name
- IMPACT PAD (NCT06686121)
- Testing
- Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control
- Where
- 8 sites in United States
- Volunteers
- 386 people
- Sponsor
- Northwestern University
Peripheral Artery Disease, Claudication, Intermittent
Passive Calf Stretching Therapy in Peripheral Artery Disease
The goal of this clinical trial is to assess the effects of passive calf muscle stretching in patients diagnosed with peripheral artery disease (PAD). The main question it aims to answer are: 1.
- Trial name
- NCT06041880
- Testing
- Passive calf muscle stretching device
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Penn State University
Peripheral Arterial Disease (PAD), Ankle Brachial Index
Automated ABPI in Peripheral Arterial Disease a Pilot Study
The aim of this pilot study is to investigate the diagnostic accuracy of two automated ABPI devices across the spectrum of PAD (asymptomatic PAD, suspected symptomatic PAD [IC; including mild moderate and severe IC based on the…
- Conditions
- Peripheral Arterial Disease (PAD), Ankle Brachial Index, Diagnostic Accuracy, Feasibility Studies
- Trial name
- AUTO-PAD (NCT07850349)
- Testing
- MESI mTablet, BlueDop vascular Expert (BlueDopVE)
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Postoperative Delirium (POD), Peripheral Arterial Disease
Effect of Preoperative Ultrasound-Guided Stellate Ganglion Block on Postoperative Delirium in Older Adults Undergoing Elective Peripheral Endovascular Intervention
This randomized controlled trial will evaluate whether preoperative ultrasound-guided stellate ganglion block reduces the incidence of postoperative delirium in adults aged 60 years or older undergoing elective peripheral…
- Trial name
- NCT07848113
- Testing
- ropivacaine
- Volunteers
- 168 people
- Sponsor
- Assiut University
Chronic Limb Threatening Ischemia, Chronic Limb-Threatening Ischemia
ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice.
- Trial name
- ORACLE (NCT07270562)
- Testing
- Stealth 360™ Peripheral Orbital Atherectomy System from Abbott
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Chronic Limb Threatening Ischemia, Chronic Limb-Threatening Ischemia
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings.
- Trial name
- RESCUE (NCT07270575)
- Testing
- Esprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring